| Literature DB >> 34124339 |
Philip Brainin1,2, Søren Lindberg2, Flemming J Olsen2, Sune Pedersen2, Allan Iversen2, Søren Galatius3, Thomas Fritz-Hansen2, Gunnar Gislason2,4, Peter Søgaard5,6, Rasmus Møgelvang4,7,8, Tor Biering-Sørensen2,9.
Abstract
BACKGROUND: Early systolic lengthening (ESL), a paradoxical stretch of myocardial fibers, has been linked to loss of myocardial viability and contractile dysfunction. We assessed the long-term prognostic potential of ESL in coronary artery bypass graft (CABG) patients.Entities:
Keywords: A, late transmitral inflow velocity; CABG, coronary artery bypass graft; CK-MB, creatine kinase myocardial band; Deformation; E, early transmitral inflow velocity; ESL, early systolic lengthening; GLS, global longitudinal strain; HR, hazard ratio; IDI, integrated discrimination improvement; IQR, interquartile range; LV, left ventricular; LVEF, left ventricular ejection fraction; NRI, net reclassification index; Prognosis; Revascularization; Systolic lengthening; e’, early diastolic tissue velocity
Year: 2021 PMID: 34124339 PMCID: PMC8175274 DOI: 10.1016/j.ijcha.2021.100799
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Fig. 1Title: Schematic drawing of speckle tracking profile. Legend: Longitudinal strain profile displaying early systolic lengthening as indicated. ESL: early systolic lengthening.
Population characteristics by tertiles of early systolic lengthening amplitude.
| Tertiles of ESL amplitude | 1st tertile (n = 237) | 2nd tertile (n = 236) | 3rd tertile (n = 236) | P trend |
|---|---|---|---|---|
| Cut-off | <6% | 6–10% | >10% | |
| Age, years | 67 ± 9 | 68 ± 9 | 68 ± 9 | 0.47 |
| Male, n(%) | 202 (85%) | 198 (84%) | 200 (85%) | 0.78 |
| Body mass index, kg/m2 | 27 ± 3 | 28 ± 4 | 27 ± 4 | 0.20 |
| Diabetes, n(%) | 53 (22%) | 65 (28%) | 58 (25%) | 0.37 |
| Hypertension, n(%) | 151 (64%) | 167 (71%) | 166 (70%) | 0.06 |
| Peripheral artery disease, n(%) | 28 (12%) | 24 (10%) | 28 (12%) | 0.87 |
| Hypercholesterolemia, n(%) | 157 (66%) | 152 (64%) | 142 (60%) | 0.16 |
| Chronic obstructive pulmonary disease, n(%) | 17 (7%) | 16 (7%) | 22 (9%) | 0.29 |
| CCS Angina Score | 0.66 | |||
| 1 | 22 (9%) | 16 (7%) | 20 (9%) | |
| 2 | 181 (76%) | 185 (78%) | 187 (79%) | |
| 3 | 31 (13%) | 33 (14%) | 28 (12%) | |
| 4 | 3 (1%) | 2 (1%) | 1 (<1%) | |
| Prior myocardial infarction, n(%) | 59 (25%) | 48 (20%) | 61 (26%) | 0.81 |
| Urea, mmol/L | 4.7 [3.9, 5.7] | 4.8 [4.1, 6.1] | 5.0 [4.1, 6.4] | 0.011 |
| Hemoglobin, mmol/L | 8.5 ± 0.9 | 8.4 ± 0.8 | 8.4 ± 0.9 | 0.20 |
| Platelets, 109/L | 259 [217, 309] | 263 [222, 311] | 269 [227, 329] | 0.046 |
| Leukocytes, 109/L | 8 [7,9] | 8 [7,9] | 8 [7,10] | 0.022 |
| C-reactive protein, mg/L | 2 [2,9] | 4 [2,9] | 5 [2,10] | 0.018 |
| Creatinine, µmol/L | 92 [81, 104] | 96 [83, 109] | 99 [84, 113] | <0.001 |
| Troponin I, µg/L | 7 [4,11] | 7 [4,11] | 6 [3,10] | 0.08 |
| Creatine kinase MB, µg/L | 29 [22,39] | 27 [20,38] | 26 [20,39] | 0.14 |
| Indication, n(%) | 0.17 | |||
| Stable angina pectoris | 122 (52%) | 120 (51%) | 111 (47%) | |
| Non-STEMI or UAP | 94 (40%) | 95 (40%) | 92 (39%) | |
| STEMI | 21 (9%) | 21 (9%) | 33 (14%) | |
| Left main stenosis, n(%) | 97 (41%) | 90 (38%) | 73 (31%) | 0.028 |
| Unstable at operation, n(%) | 8 (3%) | 17 (7%) | 12 (5%) | 0.38 |
| Extra corporal perfusion time, min | 82 ± 26 | 81 ± 23 | 81 ± 23 | 0.45 |
| Three vessel disease | 185 (78%) | 190 (81%) | 187 (79%) | 0.70 |
| LV ejection fraction, % | 54 ± 9 | 50 ± 11 | 46 ± 13 | <0.001 |
| LV mass index, g/m2 | 88 ± 24 | 95 ± 25 | 105 ± 44 | <0.001 |
| Left atrial volume index, ml/m2 | 26 ± 10 | 25 ± 10 | 25 ± 10 | 0.58 |
| E/e’ | 10 ± 3 | 11 ± 4 | 11 ± 5 | 0.005 |
| E/A | 1.1 ± 0.5 | 1.0 ± 0.4 | 1.0 ± 0.5 | 0.003 |
| TAPSE, cm | 2.5 ± 0.5 | 2.4 ± 0.4 | 2.3 ± 0.5 | <0.001 |
| Wall motion score index | 1.1 ± 0.3 | 1.2 ± 0.4 | 1.4 ± 0.5 | <0.001 |
| Global longitudinal strain, % | −16.7 ± 3.0 | −14.8 ± 3.1 | −12.6 ± 3.9 | <0.001 |
ESL: early systolic lengthening, CCS: Canadian Cardiovascular Society, MB: myocardial band, STEMI: ST-elevated myocardial infarction, UAP: unstable angina pectoris, LV: left ventricular, TAPSE: tricuspid annular plane systolic excursion.
Association between parameters of early systolic lengthening and endpoint events.
| Cardiovascular death HR [95%CI] | P | All-cause mortality HR [95%CI] | P | |
|---|---|---|---|---|
| ESL amplitude, per 1% increase | ||||
| Unadjusted | 1.37 [1.13–1.66] | 0.001 | 1.31 [1.13–1.54] | 0.001 |
| Model 1* | 1.35 [1.09–1.68] | 0.006 | 1.29 [1.08–1.54] | 0.004 |
| Model 2† | 1.54 [1.15–2.06] | 0.004 | 1.41 [1.14–1.74] | 0.001 |
| ESL duration, per 10 ms increase | ||||
| Unadjusted | 1.17 [1.08–1.26] | <0.001 | 1.14 [1.07–1.21] | <0.001 |
| Model 1* | 1.12 [1.02–1.23] | 0.016 | 1.09 [1.01–1.17] | 0.031 |
| Model 2† | 1.13 [1.00–1.26] | 0.043 | 1.10 [1.01–1.20] | 0.037 |
ESL: early systolic lengthening.
*Model 1: EuroSCORE II.
†Model 2: Age, sex, diabetes, peripheral artery disease, Canadian Cardiovascular Society Angina Score, creatinine, hemoglobin, coronary artery bypass graft indication, left main stenosis, left ventricular ejection fraction, E/e’, wall motion score index and global longitudinal strain.
Fig. 2A–C. Title: Cubic spline models and Forest plot. Legend: Association between amplitude of early systolic lengthening stratified by sex and the risk of cardiovascular death (A) and all-cause mortality (B). The red line indicates women and blue line men. Dotted lines indicate 95% confidence intervals. (C) Associations between parameters of early systolic lengthening amplitude (per 1% increase), duration (per 10 ms increase) and endpoint events stratified by sex. Associations that remained significant after adjusting for EuroSCORE II are indicated by (*). ESL: early systolic lengthening. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Association between ESL and selected echocardiographic parameters.
| ESL amplitude per 1% increase | ESL duration per 10 ms increase | |||||
|---|---|---|---|---|---|---|
| Coefficient (β) | Standardized coefficient (β) | P | Coefficient (β) | Standardized coefficient (β) | P | |
| LV ejection fraction | −0.02 | −0.23 | <0.001 | −0.09 | −0.41 | <0.001 |
| LV mass index | 0.004 | 0.18 | <0.001 | 0.02 | 0.26 | <0.001 |
| E/e’ | 0.02 | 0.08 | 0.06 | 0.12 | 0.21 | <0.001 |
| TAPSE | −0.002 | −0.12 | 0.001 | −0.11 | −0.19 | <0.001 |
| Wall motion score index | 0.49 | 0.25 | <0.001 | 2.57 | 0.43 | <0.001 |
| Global longitudinal strain | 0.09 | 0.42 | <0.001 | 0.42 | 0.63 | <0.001 |
ESL: early systolic lengthening, LV: left ventricular, TAPSE: tricuspid annular plane systolic excursion.
All analyses are adjusted for age and sex.